Trial Profile

A Phase I, Randomized, Open-Label, Crossover-Design, Single-Dose Study to Investigate the Safety, Tolerability and Comparative Bioavailability of Oral Edaravone Administered Orally and Via a Nasogastric Tube (NGT) in Healthy Adult Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 20 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Edaravone (Primary) ; Edaravone (Primary)
Indications Amyotrophic lateral sclerosis; Cerebral infarction; Liver disorders; Stroke
Focus Pharmacokinetics
Sponsors Mitsubishi Tanabe Pharma Corporation

31 Oct 2025 According to Tanabe Pharma Corporation, Mitsubishi Tanabe Pharma America is now called Tanabe Pharma America
31 Oct 2025 According to a Tanabe Pharma Corporation media release, Mitsubishi Tanabe Pharma Corporation is now called Tanabe Pharma Corporation.
11 Mar 2022 According to a Mitsubishi Tanabe Pharma America media release, data from this study will be presented at the 2022 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com